Among adults with spinal muscular atrophy (SMA) type 3, those with greater motor impairment tend to score better on…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has extended its approval of Evrysdi (risdiplam) to treat babies with spinal muscular…
A committee of the Canadian Agency for Drugs and Technologies in Health (CADTH) has issued a draft recommendation advising…
Treatment with Spinraza (nusinersen) modestly improved muscle strength and stabilized motor function for adults with spinal muscular atrophy…
For parents, protecting the health and well-being of a child with spinal muscular atrophy (SMA) was a top priority…
Children with spinal muscular atrophy (SMA) type 1 who started treatment with Evrysdi (risdiplam) in the first months of…
Treatment with the experimental muscle-directed therapy apitegromab improved motor function for many of the children and young adults with…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Researchers in Hong Kong have shared a case report about how they were inspired and humbled by a teenage girl…
Verana Health has launched a service called Neurology Qdata, which contains disease-specific datasets to help facilitate neuroscience research and…